Statin use for CVD may lower risk for COVID-19 hospitalizations, deaths

Statin use for primary prevention of CVD was associated with lower risk for COVID-19 hospitalizations and in-hospital deaths, according to findings from a cohort study published in the Journal of the American Heart Association.
“Statins are now known to be beneficial in primary prevention, decreasing all-cause mortality, cardiovascular disease, coronary heart disease and stroke,” Kim Bouillon, MD, PhD, of the department of epidemiology and public health at the University College London, and colleagues wrote. “Furthermore, there is no evidence of any serious harm caused by

Statin use for primary prevention of CVD was associated with lower risk for COVID-19 hospitalizations and in-hospital deaths, according to findings from a cohort study published in the Journal of the American Heart Association.
“Statins are now known to be beneficial in primary prevention, decreasing all-cause mortality, cardiovascular disease, coronary heart disease and stroke,” Kim Bouillon, MD, PhD, of the department of epidemiology and public health at the University College London, and colleagues wrote. “Furthermore, there is no evidence of any serious harm caused by